Table 1.
Characteristics of skin cancers treated during periods 1 vs. 2
| Period 1 (n = 372) | Period 2 (n = 231) | p value | ||
|---|---|---|---|---|
|
Total (n = 603) |
Upgraded tumors | 23 (6.2%) | 25 (10.8%) | 0.0407 |
| Days (IQR) from initial biopsy to Mohs surgery | 79 (59–107) | 66 (41–107) | 0.0085 | |
| Number of Mohs stages per tumor: | 0.0016 | |||
| 1 | 195 (52.4%) | 150 (64.9%) | ||
| 2 | 131 (35.2%) | 65 (28.1%) | ||
| 3 | 31 (8.3%) | 6 (2.6%) | ||
| 4–6 | 15 (4.0%) | 10 (4.3%) | ||
|
BCC (n = 260) |
Upgraded tumors | 17 (9.4%) | 22 (27.9%) | 0.0001 |
| Days (IQR) from initial biopsy to Mohs surgery | 99 (74–114) | 101 (63–127) | 0.8396 | |
| Number of Mohs stages per tumor: | 0.1817 | |||
| 1 | 72 (39.8%) | 37 (46.8%) | ||
| 2 | 79 (43.7%) | 33 (41.8%) | ||
| 3 | 19 (10.5%) | 3 (3.8%) | ||
| 4–6 | 11 (6.1%) | 6 (7.6%) | ||
| SCC/SCCIS (n = 334) | Upgraded tumors | 6 (3.2%) | 3 (2.0%) | 0.7363 |
| Days (IQR) from initial biopsy to Mohs surgery | 65 (48–90) | 50 (26–93) | 0.0154 | |
| Number of Mohs stages per tumor: | 0.0827 | |||
| 1 | 120 (64.9%) | 112 (75.2%) | ||
| 2 | 51 (27.6%) | 30 (20.1%) | ||
| 3 | 11 (6.0%) | 3 (2.0%) | ||
| 4–6 | 3 (1.6%) | 4 (2.7%) |
BCC basal cell carcinoma, SCC squamous cell carcinoma, SCCIS squamous cell carcinoma in situ, IQR interquartile range